Biopharma industry's arguments on rebate pass-through to patients appear to carry the day at Senate HELP Committee hearing.
Senate Health, Education, Labor and Pensions Committee Chairman Lamar Alexander, R-Tenn., is frustrated with arguments by safety net hospitals that they should not be required to disclose how they use the savings from outpatient drug discounts provided under the 340B program.
At a March 15 committee hearing he also focused attention on whether the discounts are going toward reducing the cost...
Expanded confidential pricing for pharmaceuticals is intended to help manage medicines expenditure, according to Amgros, the procurement agency that will negotiate the prices.
Incentives for repurposed drugs proposed as part of the EU pharma reform package are a “great step forward,” but more recognition is needed from payers and regulators to leverage the benefits of these medicines, experts say.
John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.
The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.
John Crowley discussed how he prioritizes industry’s many competing challenges in a Pink Sheet interview at the BIO International Convention.
The government has explained how to navigate the UK’s regulatory and market access funding mechanisms.
The Council of the EU’s vision for the pharma reform package includes a stronger role for member states regarding the supply of medicines and the prevention of indication-stacking for orphan drugs.
